X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1117) 1117
Publication (109) 109
Book Review (13) 13
Book Chapter (5) 5
Reference (3) 3
Web Resource (3) 3
Book / eBook (2) 2
Conference Proceeding (2) 2
Magazine Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (815) 815
nootropic agents - pharmacology (639) 639
male (559) 559
index medicus (557) 557
rats (437) 437
humans (432) 432
pharmacology & pharmacy (412) 412
nootropic agents - therapeutic use (320) 320
neurosciences (300) 300
mice (296) 296
nootropic agents - chemistry (242) 242
alzheimers-disease (218) 218
chemistry, medicinal (201) 201
female (201) 201
memory (195) 195
alzheimer's disease (192) 192
alzheimer disease - drug therapy (187) 187
memory - drug effects (166) 166
rats, wistar (161) 161
biochemistry & molecular biology (159) 159
brain (158) 158
cognition - drug effects (156) 156
maze learning - drug effects (155) 155
nootropic agents - administration & dosage (143) 143
dose-response relationship, drug (142) 142
disease models, animal (134) 134
avoidance learning - drug effects (118) 118
brain - drug effects (117) 117
rats, sprague-dawley (115) 115
hippocampus - drug effects (113) 113
brain - metabolism (110) 110
cognition (103) 103
neurons - drug effects (99) 99
behavior, animal - drug effects (91) 91
nootropic agents - chemical synthesis (90) 90
neurons - metabolism (89) 89
analysis (88) 88
oxidative stress (88) 88
nootropic agents - pharmacokinetics (85) 85
hippocampus - metabolism (84) 84
plant extracts - pharmacology (84) 84
dementia (81) 81
hippocampus (81) 81
neuroprotective agents - pharmacology (81) 81
structure-activity relationship (79) 79
acetylcholinesterase - metabolism (76) 76
cholinesterase inhibitors - pharmacology (72) 72
alzheimer disease - metabolism (70) 70
nootropic agents - isolation & purification (70) 70
behavioral sciences (69) 69
acetylcholinesterase (68) 68
adult (67) 67
psychiatry (66) 66
time factors (66) 66
nootropic agents - metabolism (65) 65
cognition disorders - drug therapy (64) 64
drug design (64) 64
long-term potentiation (64) 64
mice, inbred c57bl (63) 63
motor activity - drug effects (63) 63
neurons (63) 63
rodents (63) 63
aged (62) 62
article (62) 62
middle aged (62) 62
cognitive ability (59) 59
chemistry, multidisciplinary (58) 58
memory disorders - drug therapy (58) 58
plant sciences (56) 56
brain chemistry - drug effects (55) 55
donepezil (55) 55
neurology (55) 55
rat (55) 55
oxidative stress - drug effects (54) 54
amyloid beta-peptides - metabolism (53) 53
double-blind method (53) 53
pharmacology (53) 53
plant extracts - therapeutic use (53) 53
scopolamine (53) 53
cholinesterase inhibitors - chemistry (52) 52
piracetam (52) 52
nootropic agents - adverse effects (51) 51
phytotherapy (51) 51
impairment (50) 50
nerve tissue proteins - metabolism (50) 50
aging (48) 48
in vitro techniques (48) 48
molecular structure (47) 47
rat-brain (47) 47
antioxidants - pharmacology (45) 45
neuroprotection (45) 45
piperidines - pharmacology (45) 45
acetylcholine (44) 44
alzheimers disease (44) 44
antioxidants (44) 44
cholinesterase inhibitors - therapeutic use (44) 44
cells, cultured (43) 43
research (43) 43
treatment outcome (43) 43
activation (42) 42
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1084) 1084
Russian (33) 33
Chinese (4) 4
Spanish (4) 4
German (2) 2
Japanese (2) 2
Czech (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes... 
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 40 - 55
Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called protein amyloids.... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 04/2012, Volume 55, Issue 7, pp. 3076 - 3087
Furoxans (1,2,5-oxadiazole-N-oxides) are thiol-bioactivated NO-mimetics that have not hitherto been studied in the CNS. Incorporation of varied substituents... 
IN-VITRO | CHEMISTRY, MEDICINAL | ALZHEIMERS-DISEASE | THERAPEUTIC AGENTS | MOUSE MODEL | NITRIC-OXIDE | BIOLOGICAL EVALUATION | NITRATE ESTER | LONG-TERM POTENTIATION | HIPPOCAMPAL-NEURONS | PROTEASE INHIBITORS | Nitric Oxide Donors - chemistry | Peptidomimetics - chemical synthesis | Stereoisomerism | Crystallography, X-Ray | Neurons - cytology | Guanylate Cyclase - antagonists & inhibitors | Structure-Activity Relationship | Hippocampus - drug effects | Quinoxalines - pharmacology | Neuroprotective Agents - pharmacology | Long-Term Potentiation - drug effects | Oxadiazoles - pharmacology | Cysteine - metabolism | Nitric Oxide Donors - pharmacology | Neurons - drug effects | Oxadiazoles - chemistry | Synapses - drug effects | Peptidomimetics - pharmacology | Neuroprotective Agents - chemistry | Oxadiazoles - chemical synthesis | Signal Transduction | Amyloid beta-Peptides - toxicity | Synapses - physiology | Cells, Cultured | Rats | Nitric Oxide - physiology | Soluble Guanylyl Cyclase | Peptidomimetics - chemistry | Nootropic Agents - chemical synthesis | Nootropic Agents - chemistry | Neuroprotective Agents - chemical synthesis | Animals | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Nitric Oxide Donors - chemical synthesis | Hippocampus - physiology | In Vitro Techniques | Nootropic Agents - pharmacology | OXYGEN | THIOLS | PEPTIDES | LEARNING | CELL CULTURES | GLUCOSE | INORGANIC, ORGANIC, PHYSICAL AND ANALYTICAL CHEMISTRY | THERAPEUTIC USES | MODULATION | Neuroprotection | Furoxan | Alzheimer's disease | Amyloid Beta | Nitric oxide | Synaptic plasticity
Journal Article
AAPS Journal, ISSN 1550-7416, 04/2013, Volume 15, Issue 2, pp. 324 - 336
The therapeutic effects of curcumin in treating Alzheimer's disease (AD) depend on the ability to penetrate the blood-brain barrier. The latest nanoparticle... 
nanocurcumin | pharmacokinetic | Alzheimer's disease | oral route | behavior tests | PERMEABILITY | MEMORY DEFICITS | AMYLOID-BETA PROTEIN | FORMULATION | MICROPARTICLES | CELLULAR UPTAKE | BIOAVAILABILITY | MOUSE MODEL | A-BETA | CHEMOPREVENTIVE AGENT | PHARMACOLOGY & PHARMACY | Memory - drug effects | Curcumin - chemistry | Male | Polyethylene Glycols - chemistry | Curcumin - administration & dosage | Alzheimer Disease - pathology | Brain - metabolism | Nanoparticles | Plaque, Amyloid | Madin Darby Canine Kidney Cells | Behavior, Animal - drug effects | Female | Alzheimer Disease - psychology | Lactates - chemistry | Disease Models, Animal | Administration, Oral | Conditioning (Psychology) - drug effects | Drug Stability | Nootropic Agents - pharmacokinetics | Curcumin - pharmacokinetics | Alzheimer Disease - drug therapy | Mice, Transgenic | Technology, Pharmaceutical - methods | Nootropic Agents - blood | Permeability | Maze Learning - drug effects | Nootropic Agents - chemistry | Chemistry, Pharmaceutical | Blood-Brain Barrier - metabolism | Brain - drug effects | Particle Size | Fear | Povidone - chemistry | Animals | beta-Cyclodextrins - chemistry | Nootropic Agents - administration & dosage | Dogs | Brain - pathology | Mice | Alzheimer Disease - genetics | Nanotechnology | Alzheimer Disease - blood | Brain | Powders | Analysis | Drugstores | Medical tests | Cyclodextrins | Biopolymers | Polyols | Block copolymers
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2005, Volume 48, Issue 23, pp. 7223 - 7233
Journal Article
Lipids in Health and Disease, ISSN 1476-511X, 05/2017, Volume 16, Issue 1, pp. 1 - 17
The current review article is an attempt to explain the therapeutic potential of mangiferin, a bioactive compound of the mango, against lifestyle-related... 
Bioactive molecules | Nutrition | Toxicity | Health claims | Mangiferin | Human cancers | OXIDATIVE STRESS | LIPID-PEROXIDATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MYELOID-LEUKEMIA CELLS | LUNG CARCINOGENESIS | BREAST-CANCER CELLS | IN-VITRO | NUTRITION & DIETETICS | STREPTOZOTOCIN-DIABETIC RATS | SWISS ALBINO MICE | INDICA L. EXTRACT | NF-KAPPA-B | Mangifera - chemistry | Antioxidants - chemistry | Cardiovascular Diseases - drug therapy | Humans | Neuralgia - pathology | Cardiovascular Diseases - pathology | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - isolation & purification | Antineoplastic Agents, Phytogenic - therapeutic use | Cognitive Dysfunction - drug therapy | Hypoglycemic Agents - therapeutic use | Xanthones - chemistry | Xanthones - therapeutic use | Xanthones - isolation & purification | Hyperlipidemias - drug therapy | Nootropic Agents - isolation & purification | Nootropic Agents - therapeutic use | Antineoplastic Agents, Phytogenic - chemistry | Hypoglycemic Agents - chemistry | Cognitive Dysfunction - pathology | Nootropic Agents - chemistry | Neuralgia - drug therapy | Neoplasms - drug therapy | Hypoglycemic Agents - isolation & purification | Antioxidants - therapeutic use | Anti-Inflammatory Agents - chemistry | Antioxidants - isolation & purification | Hyperlipidemias - pathology | Diabetes Mellitus, Type 2 - pathology | Oxidative Stress - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Neoplasms - pathology | Antineoplastic Agents, Phytogenic - isolation & purification | Dehydrogenases | Transcription | Lipid peroxidation | Lipids | Iron | Glucose | Matrix metalloproteinase | Kinases | Macrophages | Metastases | Antioxidants | β-catenin | Mitochondria | Enzymatic activity | Bioactive compounds | Rodents | Cell cycle | Antibacterial activity | Metalloproteinase | Gram-negative bacteria | Colon | Enzymes | Free radicals | Immunomodulation | Diabetes mellitus | Tumor necrosis factor-α | Metabolism | Nitric-oxide synthase | Flavonoids | Monocytes | Nitric oxide | Isoforms | Cancer | Matrilysin | Apoptosis
Journal Article
ELIFE, ISSN 2050-084X, 04/2015, Volume 4, p. e07314
The general translation initiation factor eIF2 is a major translational control point. Multiple signaling pathways in the integrated stress response... 
GUANINE-NUCLEOTIDE-EXCHANGE | UNFOLDED PROTEIN RESPONSE | 40S RIBOSOMAL-SUBUNIT | OPEN READING FRAMES | MESSENGER-RNA | BIOLOGY | TRANSLATION INITIATION | INITIATION-FACTOR EIF2B | VANISHING WHITE-MATTER | MAMMALIAN-CELLS | GENETIC INTERACTION MAPS | RNA, Small Interfering - genetics | Phosphorylation | Humans | Thapsigargin - antagonists & inhibitors | Acetamides - pharmacology | Structure-Activity Relationship | Protein Subunits - metabolism | Acetamides - chemical synthesis | Neuroprotective Agents - pharmacology | Cyclohexylamines - pharmacology | Eukaryotic Initiation Factor-2B - genetics | HEK293 Cells | Binding Sites | Genes, Reporter | Protein Subunits - genetics | Gene Expression | Neuroprotective Agents - chemistry | Cyclohexylamines - chemical synthesis | Endoplasmic Reticulum Stress - drug effects | Bacterial Proteins - genetics | Cyclohexylamines - chemistry | Nootropic Agents - chemical synthesis | Nootropic Agents - chemistry | Neuroprotective Agents - chemical synthesis | Acetamides - chemistry | High-Throughput Screening Assays | K562 Cells | Protein Binding | Thapsigargin - pharmacology | Bacterial Proteins - metabolism | Luminescent Proteins - genetics | Eukaryotic Initiation Factor-2B - metabolism | Protein Subunits - antagonists & inhibitors | HeLa Cells | Eukaryotic Initiation Factor-2B - antagonists & inhibitors | Nootropic Agents - pharmacology | Protein Multimerization - drug effects | Luminescent Proteins - metabolism | RNA, Small Interfering - metabolism | Cell culture | Transcription factors | Neurodegenerative diseases | Serine | Translation initiation | Cognitive ability | Kinases | Proteins | Protein synthesis | Stress response | Dimerization | Long-term depression | Binding sites
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2016, Volume 59, Issue 1, pp. 114 - 131
Journal Article
Progress in Neurobiology, ISSN 0301-0082, 01/2012, Volume 96, Issue 1, pp. 32 - 45
Journal Article
ChemMedChem, ISSN 1860-7179, 07/2018, Volume 13, Issue 13, pp. 1262 - 1274
Oxoisoaporphine alkaloids are a family of oxoisoquinoline‐derived alkaloids that were first isolated from the rhizome of Menispermum dauricum DC.... 
natural products | biological activity | total synthesis | substituent effects | alkaloids | CHEMISTRY, MEDICINAL | MITOCHONDRIAL FUNCTIONS | VIVO ANTITUMOR-ACTIVITY | TUMOR-CELL APOPTOSIS | BETA-AMYLOID AGGREGATION | TELOMERASE ACTIVITY | BIOLOGICAL EVALUATION | PHARMACOLOGY & PHARMACY | MENISPERMUM-DAURICUM | ACETYLCHOLINESTERASE INHIBITORS | DUAL INHIBITORS | G-QUADRUPLEX DNA | Anti-Infective Agents - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Alzheimer Disease - drug therapy | Structure-Activity Relationship | Nootropic Agents - chemical synthesis | Antineoplastic Agents - chemistry | Nootropic Agents - chemistry | Anti-Infective Agents - chemical synthesis | Aporphines - chemical synthesis | Aporphines - pharmacology | Antidepressive Agents - therapeutic use | Animals | Anti-Infective Agents - chemistry | Antidepressive Agents - chemistry | Antidepressive Agents - chemical synthesis | Cell Line, Tumor | Antidepressive Agents - pharmacology | Antineoplastic Agents - pharmacology | Molecular Structure | Aporphines - chemistry | Nootropic Agents - pharmacology | Alkaloids | Care and treatment | Antidepressants | Alzheimer's disease | Cancer | Biological properties | Neurodegenerative diseases | Amyloid | Inhibition | Alzheimers disease | Amine oxidase (flavin-containing) | Cholinesterase | Anticancer properties | Structure-function relationships
Journal Article